These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30690710)

  • 1. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
    Ott PA; Pavlick AC; Johnson DB; Hart LL; Infante JR; Luke JJ; Lutzky J; Rothschild NE; Spitler LE; Cowey CL; Alizadeh AR; Salama AK; He Y; Hawthorne TR; Bagley RG; Zhang J; Turner CD; Hamid O
    Cancer; 2019 Apr; 125(7):1113-1123. PubMed ID: 30690710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
    Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
    J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.
    Ott PA; Hamid O; Pavlick AC; Kluger H; Kim KB; Boasberg PD; Simantov R; Crowley E; Green JA; Hawthorne T; Davis TA; Sznol M; Hwu P
    J Clin Oncol; 2014 Nov; 32(32):3659-66. PubMed ID: 25267741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
    Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
    J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
    Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
    Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
    Naumovski L; Junutula JR
    Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma.
    Hasanov M; Rioth MJ; Kendra K; Hernandez-Aya L; Joseph RW; Williamson S; Chandra S; Shirai K; Turner CD; Lewis K; Crowley E; Moscow J; Carter B; Patel S
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group.
    Kopp LM; Malempati S; Krailo M; Gao Y; Buxton A; Weigel BJ; Hawthorne T; Crowley E; Moscow JA; Reid JM; Villalobos V; Randall RL; Gorlick R; Janeway KA
    Eur J Cancer; 2019 Nov; 121():177-183. PubMed ID: 31586757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
    Rose AAN; Biondini M; Curiel R; Siegel PM
    Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
    Rose AA; Annis MG; Frederick DT; Biondini M; Dong Z; Kwong L; Chin L; Keler T; Hawthorne T; Watson IR; Flaherty KT; Siegel PM
    Clin Cancer Res; 2016 Dec; 22(24):6088-6098. PubMed ID: 27515299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
    Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
    Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
    Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
    Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
    Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
    JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504).
    Khan SA; Sun Z; Dahlberg S; Malhotra J; Keresztes R; Ikpeazu C; Ma P; Ramalingam SS; Pillai R
    JTO Clin Res Rep; 2021 May; 2(5):100166. PubMed ID: 34590018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.